Background: This Retrospective Study was conducted by collecting patient records from the COVID-19 registry of Parul Sevasharm Hospital. The goal of this study was to investigate the risk and mortality of COVID-19 patients with Metabolic Syndrome especially during the second wave of pandemic. Methods: This Retrospective Study was conducted by collecting patient records from the COVID-19 registry of Parul Sevasharm Hospital. The record of COVID-19 patients admitted during the second wave of pandemic (April – June, 2021) were included and analyzed for Metabolic syndrome, Demographic characteristics and Clinical Outcomes. Comorbidities were classified into the following Groups: DM (having DM with or without comorbidities), only DM (having DM without other comorbidities); HT (having HT with or without other comorbidities), only HT (having HT without other comorbidities); CVD (having CVD with or without comorbidities), only CVD (having CVD without other comorbidities). Correlation analysis was also done for sub-groups of DM+CVD, CVD+HT, HT+DM, (with or without other comorbidities). Results: Among 994 Patients with COVID-19, 748/994 (75.25%) were discharged as cured and 246 (24.74%) succumbed to death. The mean age of the study population was 52.64±14.72, in which 366 (36.82%) were Females and 628/994 (63.57%) were Males.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.